Informed Consent and Shared Decision-Making: A Requirement to Disclose to Patients Off-Label Prescriptions
Authors:
- Michael WilkesMWMichael Wilkes
- Margaret JohnsMJMargaret Johns
Open Access
- 11 November 2008
- journal article
- policy forum
- Published by Public Library of Science (PLoS) in PLOS Medicine
- Vol. 5 (11) , e223
Abstract
Michael Wilkes and Margaret Johns argue that the doctrine of informed consent should require doctors to disclose to patients when they are prescribing a drug off-label.Keywords
This publication has 13 references indexed in Scilit:
- A new reason to frown. Does Botox get into the brain? Troubling research contradicts earlier findings about the treatment.2008
- The Price of Sight — Ranibizumab, Bevacizumab, and the Treatment of Macular DegenerationNew England Journal of Medicine, 2006
- Designing a Strategy to Promote Safe, Innovative Off-Label Use of MedicationsAmerican Journal of Medical Quality, 2006
- Off-label Prescribing Among Office-Based PhysiciansArchives of internal medicine (1960), 2006
- Off-label use of prescription medication: nursing implications.2003
- Off-label or out of bounds? Prescriber and marketer liability for unapproved uses of FDA-approved drugs.2003
- Dissing disclosure: just what the doctor ordered.2002
- Prevalence of Articles With Honorary Authors and Ghost Authors in Peer-Reviewed Medical JournalsJAMA, 1998
- FDA, off-label use, and informed consent: debunking myths and misconceptions.1998
- Authorship! Authorship! Guests, ghosts, grafters, and the two-sided coin1994